[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tongji University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,71,94,114,134,161,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635299","phase-2-intranasal-dexmedetomidine-for-acute-anxiety-state-in-adults-100635299",false,"NCT07550881","Intranasal Dexmedetomidine for Acute Anxiety State in Adults","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for the Treatment of Acute Anxiety States in Adults","Inclusion Criteria:\n\n1. No gender restrictions; during screening: age must be between 18 and 65 years;\n2. Meet the criteria for acute anxiety, defined as subjective anxiety or worry accompanied by at least four associated symptoms, with a CGI-S score of ≥4;\n3. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Acute anxiety states caused by other psychoactive substances; history of abuse of psychotropic or anesthetic drugs; 2. Use of sedative-hypnotic drugs at the time of enrollment and still in the washout period; 3. Use of alpha-adrenergic agonists (e.g., norepinephrine, methoxamine, methoxamine hydrochloride, epinephrine, clonidine hydrochloride tablets, midodrine hydrochloride tablets, etc.) or beta-blockers (e.g., metoprolol, etc.) within the past 12 hours; 4. Patients with allergies to the active ingredients or components of the study drugs (e.g., dexmedetomidine) or those with a history of three or more allergic reactions to various allergens; 5. Endocrine system disorders, such as hypoglycemia, pheochromocytoma, hyperthyroidism, or hypothyroidism; 6. Cardiovascular diseases, including myocardial infarction or unstable angina within the 6 months prior to screening; heart rate \\\u003C60 beats per minute during screening; History of severe arrhythmias, such as second-degree type II atrioventricular block or higher; poorly controlled blood pressure (hypertension: systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥110 mmHg, or hypotension: systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure ≤50 mmHg); 7. Cerebrovascular diseases, such as a history of ischemic stroke or transient ischemic attack; 8. Respiratory diseases, such as asthma, pulmonary embolism, chronic obstructive pulmonary disease, or pneumonia; history of difficult airway management or assessed potential risk, such as obstructive sleep apnea syndrome or asthma; 9. History of severe hepatic or renal insufficiency; 10. History of epilepsy; 11. Pregnant or lactating women; 12. Other conditions deemed unsuitable for enrollment by the investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study employs a randomized, double-blind, placebo-controlled clinical trial design to evaluate the efficacy and safety of dexmedetomidine hydrochloride nasal spray in the treatment of acute anxiety in adults.\n\nStudy Protocol: Patients meeting the criteria for acute anxiety who provided informed consent and met the inclusion and exclusion criteria were randomized in a 1:1 ratio to the placebo group or the study drug group and entered the double-blind study. Upon enrollment, baseline assessments were conducted to evaluate the number of accompanying symptoms, subjective anxiety severity (NRS), STAI-S-6, CGI-S, and RASS. Immediately following these assessments, patients received a nasal spray of 30 μg of dexmedetomidine or an equal-volume placebo; the time of administration was recorded as 0 minutes. At 15, 30, 45, 60, 90, and 120 minutes post-administration, the NRS for subjective anxiety severity, CGI-S, and CGI-I were assessed. The count of accompanying symptoms, STAI-S-6, and RASS were re-assessed only at 15, 30, and 120 minutes post-administration. In addition, vital signs (heart rate, oxygen saturation, and blood pressure) were assessed and recorded at baseline (prior to administration) and at 15, 30, 45, 60, 90, and 120 minutes post-administration. Venous blood samples were collected prior to administration and 90-120 minutes post-administration to measure biological markers. Adverse events were monitored during a 7-day follow-up period after treatment.",[27],"Acute Anxiety States","RECRUITING","2026-06-06",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2026-04-30",{"date":36,"type":21},"2027-07-31",{"name":38,"class":39},"Tongji University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100634819","effect-of-surgical-planning-prompts-on-elective-surgery-acceptance-rate-100634819","NCT07544641","Effect of Surgical Planning Prompts on Elective Surgery Acceptance Rate","Impact of Patient Surgical Planning on Elective Surgery Acceptance Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\. Diagnosed with one of the following: age-related cataract, complicated cataract, traumatic cataract, metabolic cataract, or congenital cataract 2. Age 18+ years 3. Baseline intraocular pressure (IOP) ≤ 21 mmHg 4. Axial length 20-30 mm 5. No intraocular surgery within the past 3 months 6. Meets at least ONE of the following functional criteria:\n\n  1. Best Corrected Visual Acuity (BCVA) ≤ 0.5 and vision loss primarily attributable to cataract\n  2. Posterior subcapsular cataract with patient-reported significant impact from glare, halos, or impaired night driving\n  3. Patient-reported significant decrease in contrast sensitivity\n  4. Anisometropia or refractive error, and patient reports inability to accept spectacle correction impacting reading, daily chores, TV viewing, driving, or outdoor activities\n  5. Cataract interfering with fundus examination\u002Ftreatment (e.g., diabetic retinopathy, macular disease, uveitis)\n  6. Lens with risk of inducing glaucoma (shallow anterior chamber with family history or fellow-eye history of angle-closure, lens dislocation\u002Fsubluxation, hypermature cataract)\n\nExclusion Criteria:\n\n* Already decided to undergo or decline surgery at time of initial consultation",{"count":49,"type":21},268,[51],"NA","This randomized, double-blind, controlled trial investigates whether prompting patients facing elective cataract surgery to articulate their specific conditions for choosing surgery (a structured self-reflection intervention commonly used in Shared Decision-Making) affects their subsequent decision to undergo the procedure. Eligible cataract patients who have been informed of surgical indications at an outpatient visit will be randomly assigned 1:1 to an intervention group (structured writing about personal conditions for accepting surgery) or a control group (no writing task). Both groups read the same standardized information about cataract diagnosis and treatment, and both complete the same set of follow-up questionnaire items. Three treating physicians independently rate their degree of surgical recommendation for each patient; these ratings along with baseline clinical measures are included as covariates in the analysis. The primary outcome is whether participants register for cataract surgery within 6 months of their initial outpatient consultation. Secondary outcomes include self-reported understanding of the condition, clarity of treatment plan, condition-related anxiety, perceived urgency, perceived helpfulness of the consultation, semantic analysis of written responses, and patient experience measures.",[54],"Cataract",[54,56,57,58,59,60,61],"Shared Decision-Making","Elective Surgery","Surgical Planning","Decision Aid","Patient Autonomy","Behavioral Intervention","NOT_YET_RECRUITING","2026-04-15",{"date":65,"type":32},"2026-04-22",{"date":67,"type":21},"2026-04-13",{"date":69,"type":21},"2027-04",{"name":38,"class":39},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100620716","phase-1-a-phase-l-clinical-study-to-evalute-the-safetytolerabilitypharmacokinetic-characteristicsand-preliminary-anti-tumor-efficacy-of-hj-004-02-tablets-in-patients-with-non-squamous-non-small-cell-lung-cancer-with-epidermal-growth-factor-receptor-egfr-mutations-100620716","NCT07361237","A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations","HJ-004-02-101","Inclusion Criteria:\n\n1. Male or female, aged \\>=18 years and \\\u003C75 years\n2. Clinical diagnosis of NSCLC.\n3. Subjects must have experienced disease progression after standard therapy, or be intolerant to or unsuitable for standard therapy, or have no available standard therapy.\n4. Subjects must provide 3-5 archived tumor tissue slides\n5. Subjects must have non-squamous NSCLC with one or more positive EGFR mutations\n6. At least one measurable lesion according to RECIST v1.1 (In Phase Ia, lesions that are assessable but not measurable are acceptable).\n7. ECOG performance status score of 0-1\n8. Life expectancy \\>=12 weeks.\n9. (1) Hematologic Function:Absolute neutrophil count (ANC) \\>= 1.5×10\\^9\u002FL;Platelet count (PLT) \\>= 100×10\\^9\u002FL;Hemoglobin (HGB) \\>=9.0 g\u002FdL; (2)Hepatic Function:Total bilirubin (TBIL) \\\u003C=1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) For those without liver metastases, \\\u003C=2.5 × ULN, orFor those with liver metastases, \\\u003C=5 × ULN; (3)Renal Function:Creatinine \\\u003C=1.5 × ULN; if \\>1.5 × ULN, creatinine clearance ≥50 mL\u002Fmin \\[Creatinine clearance calculated using the Cockcroft-Gault formula (see Appendix 2: Cockcroft-Gault Formula)\\] (4)Coagulation Panel Note: For subjects receiving anticoagulant therapy, the investigator will determine whether the international normalized ratio (INR) and activated partial thromboplastin time (APTT) are within a safe therapeutic range. INR \\\u003C= 1.5×ULN;APTT \\\u003C= 1.5×ULN.\n10. Contraception is required during the trial period.\n\nExclusion Criteria:\n\n1. Within the four weeks prior to the administration of HJ-004-02 tablets, the patient had received other anti-tumor treatments such as biological therapy, immunotherapy, radiotherapy, and chemotherapy.\n2. Participation in an investigational drug study with treatment or use of an investigational device within 4 weeks before the first dose of HJ-004-02 tablets. 3. Anticipated need for any other form of anti-tumor therapy during the study.\n\n4\\. Toxicity from prior therapy has not resolved to \\\u003C=Grade 1 according to NCI-CTCAE v5.0 criteria, with the exception of alopecia and long-term stable chronic disease.\n\n5\\. Presence of histological transformation, and ALK, HER2, KRAS, ROS1, FGFR, NTRK, RET, BRAF gene abnormalities in EGFR-TKI non-dependent drug resistance; 6. History of severe eye disorder prior. 7. History of severe dermatosis prior. 8. Subjects who have gastrointestinal disease 9. Subjects who have received treatment with P-gp inhibitors, potent CYP3A4 inhibitors 10. Subjects with uncontrolled pleural effusion, ascites, or pericardial effusion requiring repeated drainage procedures, as judged by the investigator.\n\n11\\. Subjects with symptomatic brain metastasis, metastases to meninges, or spinal cord compression.\n\n12\\. Subjects with an active infection of \\>=Grade 2 13. Subjects with a history of allergy to the active ingredient or inactive excipients of HJ-004-02 tablets, or to drugs with a similar chemical structure or class to HJ-004-02 tablets.\n\n14\\. Subjects with a confirmed immunodeficiency disease, and\u002For a positive HIV test result at screening.\n\n15\\. Subjects with active hepatitis B 16. Subjects with positive syphilis antibodies and a positive titer test. 17. Active tuberculosis. 18. Presence of a malignancy other than the indication of this study within \\\u003C=5 years before the first dose of HJ-004-02 tablets 19. Subjects who have had a clinically significant cerebrovascular disorder within 6 months before the first dose of HJ-004-02 tablets, 20. Subjects who have undergone major surgery or severe traumatic injury within 4 weeks before the first dose of HJ-004-02 tablets, or who are expected to require major surgery during the study.\n\n21\\. History of interstitial lung disease (ILD) 22. Subjects with any haemorrhagic diathesis or coagulopathy 23. Subjects with a known psychiatric illness 24. Those who have received a live attenuated vaccine within 28 days before the first dose of the investigational product or plan to receive one during the study and within 60 days after the end of investigational product treatment.\n\n25\\. Female subjects who are pregnant or breastfeeding. 26. Any other condition that, in the investigator's judgment, would hinder the subject's participation in the clinical study.","75 Years",{"count":80,"type":21},36,[82],"PHASE1","Single dose: Fasting, oral administration, as a single dose, taken with warm water. Multiple doses: Fasting, oral administration, as a single dose, taken with warm water, once daily (dosing frequency may be adjusted based on study data), with 28 days as one cycle.",[85],"NSCLC (Advanced Non-small Cell Lung Cancer)","2026-01-14",{"date":88,"type":32},"2026-01-22",{"date":90,"type":21},"2025-12-30",{"date":92,"type":21},"2028-12-31",{"name":38,"class":39},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100608943","mechanistic-studies-of-chronic-copd-using-single-cell-sequencing-and-single-cell-spatial-transcriptomics-100608943","NCT07208123","Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics","A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD","Inclusion Criteria:\n\n* Receiving lung resection surgery at the hospital for any reason；\n* Diagnosed with COPD according to the 2024 GOLD guidelines；\n* Tissue samples that meet collection requirements and are either agreed to be collected or already preserved；\n\nExclusion Criteria:\n\n* Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information；\n* Combined with other factors causing obstructive airflow limitation;\n* Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;\n* Combined with Advanced lung cancer;\n* Receiving systemic immunosuppressive medications such as anti-rejection drugs;",{"count":20,"type":21},"OBSERVATIONAL","This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.",[105],"COPD","2025-09-27",{"date":108,"type":32},"2025-10-06",{"date":110,"type":21},"2025-09-30",{"date":112,"type":21},"2027-12-31",{"name":38,"class":39},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100596622","clinical-investigation-of-sympathetic-nerve-width-measurement-in-thoracoscopic-sympathectomy-100596622","NCT07047859","Clinical Investigation of Sympathetic Nerve Width Measurement in Thoracoscopic Sympathectomy","Inclusion Criteria:\n\n1. Diagnosis : Confirmed autonomic nervous dysfunction (including palmar hyperhidrosis, craniofacial hyperhidrosis, or facial blushing).\n2. Age : ≥18 years and ≤55 years.\n3. Cardiopulmonary Function :\n\n   Normal preoperative chest CT scan and electrocardiogram (ECG).\n4. Performance Status : ECOG score (see Attachment 1) of 0-1, indicating good clinical fitness and ability to perform daily activities independently.\n5. Informed Consent : Patients and their families fully understand the study's purpose, procedures, risks, and potential benefits, voluntarily sign the Informed Consent Form, and agree to participate.\n\nExclusion Criteria:\n\n1\\. Abnormal Preoperative ECG :\n\n1. Severe arrhythmias:\n\n   1. Type II second-degree or higher atrioventricular block.\n   2. Symptomatic ventricular arrhythmias.\n   3. Uncontrolled supraventricular arrhythmias (resting heart rate \\>100 bpm). These may cause inadequate cardiac output, hypoperfusion of vital organs, and increased surgical risk.\n2. Myocardial ischemia or infarction:\n\n   1. ECG showing ST-segment elevation\u002Fdepression, T-wave inversion.\n   2. Pathological Q-waves indicating myocardial infarction. 2. Abnormal Chest CT :\n\n1\\) Severe pulmonary infections (e.g., lobar pneumonia, empyema) with symptoms like fever, cough, dyspnea. Surgery increases infection risk and may lead to atelectasis or respiratory failure.\n\n2\\) Pneumothorax or tension pneumothorax:\n\n1. Significant lung collapse causing dyspnea.\n2. Tension pneumothorax requiring immediate chest tube drainage. 3) Pleural effusion (moderate\u002Flarge volume): Causes dyspnea or mediastinal shift; surgery may worsen respiratory function.\n\n   3\\. Hyperthyroidism-induced facial blushing or generalized hyperhidrosis. 4. Anesthesia Contraindications : Allergy to anesthetics or high-risk conditions (severe pulmonary\u002Fcardiac dysfunction).\n\n   5\\. Cognitive\u002FPsychiatric Impairment : Inability to provide informed consent or understand study risks.\n\n   6\\. Non-Compliance with Follow-up : Inability to adhere to postoperative visits.\n\n   7\\. Immunodeficiency Disorders : Severe immunodeficiency, AIDS, or organ transplant history.\n\n   8\\. Frailty\u002FAdvanced Age : Elderly patients with comorbidities or functional decline unfit for surgery.\n\n   9\\. Severe Organ Dysfunction : Cirrhosis, renal failure, or inability to tolerate surgery\u002Frecovery.\n\n   10\\. Active Infections : Under antibiotic treatment for pneumonia, tuberculosis, or bacterial infections.\n\n   11\\. Uncontrolled Diabetes : Poor glycemic control with complications (retinopathy, diabetic foot).\n\n   12\\. Concurrent Clinical Trials : Participation in other interventional studies affecting results.\n\n   13\\. Severe Malnutrition : Significant weight loss or nutritional deficiency increasing anesthesia\u002Fsurgical risks.\n\n   14\\. Hematologic Disorders : Anemia, thrombocytopenia, or coagulopathies affecting hemostasis\u002Frecovery.\n\n   15\\. Severe Chronic Respiratory Failure : Long-term ventilator dependence or tracheostomy.","55 Years",{"count":122,"type":21},1000,"This prospective, single-center observational study evaluates the clinical utility of intraoperative sympathetic nerve width measurement during thoracoscopic sympathectomy (ETS) for palmar\u002Fcraniofacial hyperhidrosis (PH\u002FCH) and facial blushing (FF). The study aims to correlate nerve width-measured using a novel Rapid Intraoperative Sympathetic Nerve Width System (RMSNW-OS) (±0.2mm precision)-with surgical outcomes, compensatory sweating rates, patient satisfaction, and 12-month efficacy.\n\nApproximately 1,000 patients (aged 18-55) will undergo standardized ETS at Shanghai First People's Hospital (2025-2029). Objective metrics include thermographic (palmar\u002Fforehead temperature), hemodynamic (HR\u002FBP), biochemical (catecholamines), and Doppler flow measurements. Patient-reported outcomes use diagnosis-specific binary questionnaires and the Hyperhidrosis Disease Severity Scale (HDSS).\n\nStatistical analysis will determine if nerve width predicts treatment response. Innovations include RMSNW-OS standardization and a multidimensional assessment framework to optimize ETS precision and patient quality of life.",[125],"Thoracoscopic Sympathectomy (ETS)","2025-06-30",{"date":128,"type":32},"2025-07-02",{"date":130,"type":21},"2025-07-15",{"date":132,"type":21},"2029-05-31",{"name":38,"class":39},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":160,"locationsCount":40},"100572970","phase-4-trazodone-on-nrem-sleep-stage--in-depressed-insomniac-co-morbid-patients-100572970","NCT06740188","Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients","Impact of Trazodone on Non-rapid Eye Movement Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients: A Randomized Controlled Trial","n-REMSS","Inclusion Criteria:\n\n* Outpatient or inpatient patients;\n* 18 years old ≤ 65 years old;\n* Simultaneously meet the diagnostic criteria for depression and non organic insomnia in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in the United States;\n* 17 items of Hamilton Depression Rating Scale (HAMD-17) with a total score of ≥ 17 points;\n* Pittsburgh Sleep Quality Index (PSQI) ≥ 16 points;\n* Never used related antidepressants and sedative hypnotic drugs;\n* Has a certain level of visual and auditory resolution, and no comprehension barriers;\n* Capable of independently completing scale measurements;\n* Education level above primary school;\n* Obtain written informed consent from the patient, and obtain written informed consent from the legal guardian if the patient is incapacitated during the onset of the illness.\n\nExclusion Criteria:\n\n* Patients with comorbidities such as schizophrenia, schizophrenia, bipolar disorder, mental retardation, pervasive developmental disorder, delirium, dementia, cognitive impairment, alcohol dependence, etc\n* Suffering from serious organic diseases, such as diabetes, thyroid disease, hypertension, cardiovascular disease, craniocerebral trauma, cerebral ischemia or hemorrhage;\n* Patients with narrow angle glaucoma;\n* History of epilepsy and febrile seizures;\n* Individuals with a history of drug use;\n* Positive for syphilis specific antibody and AIDS antibody;\n* According to risk assessment, there are currently serious suicide attempts or individuals who are overly agitated Pregnant or lactating women, or those planning to conceive in the near future;\n* Laboratory tests indicate the presence of liver and kidney function impairment in individuals;\n* There are other individuals who meet the relevant contraindications for antidepressants.",{"count":143,"type":21},60,[145],"PHASE4","This study used polysomnographic technology and randomly selected 60 patients who met the diagnostic criteria for depression and non-organic insomnia as stipulated in DSM-5 into an intervention group (n=30) and a control group (n=30). The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone, while the control group was given citalopram hydrobromide combined with zolpidem. Both groups underwent PSG at baseline and 1 week after medication, and were assessed with the 17-item Hamilton Depression Rating Scale, Zung Self-Rating Depression Scale, Pittsburgh Sleep Quality Index, Arnsworth Insomnia Severity Scale, Antidepressant Side Effects Checklist, and the Drug Dependence Scale neuropsychological assessment at baseline, 1, 2, and 4 weeks after medication. The study aimed to explore the effects of single use of SMAs class antidepressants versus combination with other antidepressants on non-rapid eye movement sleep stage III in patients with depression and insomnia comorbidity, and to compare the effects of depression and insomnia in the two groups.",[148],"Depressed Insomniac Co-morbid Patients",[150,151,152,153],"Trazodone","Non-rapid Eye Movement Sleep Stage","depression","insomnia","2025-02-16",{"date":156,"type":32},"2025-02-19",{"date":158,"type":32},"2025-01-01",{"date":112,"type":21},{"name":38,"class":39},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":40},"100539477","phase-2-pembrolizumab-combined-with-preoperative-chemotherapy-albumin-paclitaxelcarboplatin-neoadjuvant-therapy-for-resectable-locally-advanced-stage-iiiii-esophageal-squamous-cell-carcinoma-100539477","NCT06304350","Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II\u002FIII) Esophageal Squamous Cell Carcinoma","A Single Arm, Single Center, Phase II Clinical Study of Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II\u002FIII) Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Baseline stage resectable cII\u002FIII esophageal squamous cell carcinoma (8th UICC TNM stage);\n2. Failure to receive anti-tumor treatment for esophageal squamous cell carcinoma;\n3. Age range from 18 to 75 years old;\n4. There are no surgical contraindications in the preoperative evaluation of various organ functions;\n5. The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for participating in the study: hemoglobin ≥ 9.0g\u002FL; White blood cell count 4.0-10 × 109\u002FL; Neutrophil absolute value (ANC) ≥ 1.5 × 109\u002FL; Platelet count ≥ 100 × 109\u002FL; Total bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2.5 times the upper limit of normal values; The international standardized ratio of prothrombin time is ≤ 1.5 times the upper limit of normal values, and some prothrombin time is within the normal range; Creatinine ≤ 1.5 times the upper limit of normal value;\n6. Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors, have no history of other malignant tumors, and do not include prostate cancer patients who have received hormone therapy and have obtained DFS for more than 5 years;\n7. Expected to achieve R0 resection;\n8. Physical state ECOG 0-1;\n9. The subjects must understand and sign the informed consent form\n\nExclusion Criteria:\n\n1. Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.);\n2. Not suitable for surgery or with surgical contraindications;\n3. Have a history of other anti PD-L1\u002FPD-1 treatments;\n4. Individuals with immunodeficiency or long-term systemic steroid therapy, or those who have received any immunosuppressive therapy within 7 days prior to receiving the study drug;\n5. Individuals with active autoimmune diseases requiring systemic treatment within 2 years;\n6. Patients with poor control of heart disease\n7. Pregnant or lactating female patients;\n8. For patients with drug allergies in the protocol.\n\nExit criteria：\n\nWithdrawal cases refer to subjects who have stopped continuing treatment in clinical research due to various reasons. Subjects who experience the following situations will withdraw from the investigational treatment:\n\n1. The main indicators are missing, and more than half of the items that can be filled in CRF are missing;\n2. The surgical procedure violates the plan;\n3. Cases that are excluded due to adverse reactions are not evaluated for efficacy, but side effects should be included in the statistics;\n4. According to the researcher's opinion, continuing to participate in the study will be harmful to their health;\n5. Patients who fail to undergo non-surgical treatment due to various reasons, including malignant tumor progression, underlying disease progression, patient or their trustee requesting withdrawal, will be reported together;\n6. Missing subjects. All subjects who withdrew from the study should record their reasons for withdrawal in the CRF and their medical records. According to the ITT principle, all withdrawn cases should undergo survival analysis and toxicity evaluation for the corresponding group.",{"count":169,"type":21},25,[24],"This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII\u002FIII stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR as the main endpoint of the study",[173],"Esophageal Cancer",[175,176,177],"esophageal cancer；","Pembrolizumab；","Neoadjuvant therapy","2024-03-11",{"date":180,"type":32},"2024-03-13",{"date":182,"type":32},"2024-02-17",{"date":184,"type":21},"2026-12-31",{"name":38,"class":39},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100537369","phase-4-a-study-of-camrelizumab-combined-with-chemotherapy--thalidomide-in-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc-100537369","NCT06276933","A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLC","Inclusion Criteria:\n\n1. Age ≥18 years old, both male and female.\n2. Histopathology or cytology confirmed advanced Stage IIIB-IV non-small cell lung cancer.\n3. No prior systemic treatment to advanced NSCLC . Subjects who have received prior neo-adjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 12 months from randomization since the last chemotherapy cycle.\n4. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.\n6. Have a life expectancy of at least 3 months.\n7. All baseline laboratory requirements will be assessed.\n8. Can swallow pills normally.\n9. Remission of all acute toxic reactions to previous antitumor therapy to grade 0-1 or to the level specified in the exclusion criteria.\n10. Female Subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose, are not breastfeeding, and must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment. Male subjects whose partners are fertile women should be surgically sterilized or agree to use effective contraception during the trial period and 90 days after the last administration of the study drug, and sperm donation is not allowed during the study period.\n11. Subjects has voluntarily agreed to participate by giving written informed consent. Willing and able to follow planned visits, research treatments, laboratory tests and other test procedures.\n\nExclusion Criteria:\n\n1. Patients with non-small cell lung cancer diagnosed with other histopathological types, including patients with NSCLC containing small cell lung cancer components.\n2. Subjects with epidermal growth factor receptor (EGFR)-sensitizing mutation and\u002For anaplastic lymphoma kinase (ALK) translocation.\n3. Patients who have previously received PD-(L)1 or CTLA-4 treatment.\n4. Subjects with active CNS metastases are excluded.\n5. Subjects with active, known or suspected autoimmune disease. Participants who are in a stable state and do not require systemic immunosuppressive therapy are permitted to enroll.\n6. Congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection.\n7. Have the following poorly controlled infectious diseases: active viral hepatitis B or C; Have active TB or are currently receiving anti-TB treatment.\n8. There is past or present objective evidence of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, tissue pneumonia (such as bronchitis, vasculitis obliterans), drug-induced pneumonia, active pneumonia on CT examination, or severe impairment of lung function.\n9. Subjects with clinically significant cardiovascular and cerebrovascular diseases.\n10. Active infection (CTCAE\\> Grade 2).\n11. Diagnosed with immune deficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy not directly related to tumor treatment within 7 days prior to study enrollment; Physiological doses of glucocorticoids are permitted.\n12. Other malignancies developed within 5 years prior to admission, excluding adequately treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery.\n13. Subjects received major surgery within 4 weeks of the first dose of study treatment or planned during the study period.\n14. Subjects had administration of a live, attenuated vaccine within 4 weeks of the first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study.\n15. Subjects who are alcohol dependent or have a history of drug or substance abuse within the last 1 year.\n16. Subjects with a known neurological or mental disorder, such as epilepsy, dementia, or the presence of a peripheral nervous system disorder.\n17. Subjects had or plan to have allogeneic bone marrow transplantation or solid organ transplant.\n18. Pregnant or lactating female; The fertile subject is unwilling or unable to take effective contraceptive measures.\n19. Known allergy to the investigational drug or excipient.\n20. Received any other investigational medicine treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF.\n21. Abnormal coagulation function .Thrombosis or thromboembolic event within 6 months prior to the start of study treatment.\n22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject\\'s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.",{"count":194,"type":21},104,[145],"To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients",[198,199],"Lung Cancer","Camrelizumab","2024-02-23",{"date":202,"type":32},"2024-02-26",{"date":204,"type":21},"2024-02-22",{"date":206,"type":21},"2026-11-22",{"name":38,"class":39},""]